It could be another depressing case of follow-the-leader drug development where drug companies rush to test a similar compounds class because everyoneelseisdoingit, only to find out in the end that none of them work very well.
Doing what everyoneelseis doing playing it safe just to avoid bombing is the real gamble, because you will likely make no impression on your audience at all.